4D Molecular Therapeutics, Inc. reported its financial results for the first quarter of 2026, revealing a significant increase in collaboration and license revenue, which rose to $3.0 million from just $14,000 in the same period last year. This increase was primarily attributed to clinical trial cost-sharing and reimbursement from Otsuka Pharmaceutical Co., Ltd., following a collaboration agreement established in October 2025. Despite this revenue growth, the company continued to experience substantial operating losses, reporting a net loss of $68.8 million for the quarter, compared to a loss of $48.0 million in the first quarter of 2025.
Total operating expenses for the quarter increased by 43% to $76.7 million, driven largely by a 60% rise in research and development costs, which reached $65.0 million. This increase was mainly due to heightened clinical trial activities for the lead product candidate, 4D-150, which is being developed for wet age-related macular degeneration and diabetic macular edema. General and administrative expenses decreased by 10% to $11.7 million, reflecting a reduction in headcount in administrative roles.
As of March 31, 2026, 4D Molecular Therapeutics had cash, cash equivalents, and marketable securities totaling $457.6 million, a slight decrease from $566.7 million at the end of 2025. The company’s accumulated deficit grew to $785.1 million, indicating ongoing financial challenges as it continues to invest heavily in its product development pipeline without any products currently approved for sale. The company has indicated that it expects to continue incurring significant losses for the foreseeable future.
In terms of strategic developments, 4D Molecular Therapeutics has made notable progress in its clinical trials. The company completed enrollment for its first Phase 3 trial of 4D-150 ahead of schedule, with topline data expected in the first half of 2027. Additionally, the company has entered into a collaboration agreement with Otsuka, which includes an upfront payment of $85 million and potential milestone payments totaling up to $335.5 million, along with royalties on net sales in the Otsuka territory.
Looking ahead, 4D Molecular Therapeutics plans to continue its focus on advancing its product candidates through clinical trials while seeking additional funding to support its operations. The company has expressed the need for substantial capital to finance its ongoing research and development efforts, and it may pursue various financing options, including equity offerings and collaborations, to meet its future funding requirements.
About 4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc. is a late-stage biotechnology company specializing in innovative genetic medicines for ophthalmology and pulmonology. Its lead product, 4D-150, targets retinal diseases like wet AMD and diabetic macular edema, while 4D-710 aims to treat cystic fibrosis. Utilizing its proprietary Therapeutic Vector Evolution platform, the company addresses significant unmet medical needs, focusing on durable therapies with reduced treatment burdens. 4DMT is positioned for impactful advancements in patient care.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.